Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g.,
anxiety,
epilepsy,
schizophrenia and other psychotic disorders, Parkinson's
disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5
antagonist compound of the invention. Specific examples of partial MgluR5 antagonists provided include those compounds having the formula: wherein: Z is, independently N or —CH—, provided that one, and only one Z is N; R is
halogen (e.g., Br, F and the like),
alkyl (e.g., methyl), alkenyl (e.g., CH═CH2,
aryl (e.g., phenyl), heterocyclic (e.g., thiophenyl).